208.53 USD
↗ 0.03 (0.01%)PRE MARKET (AS OF 08:09 AM EDT)
Open?$207.52
High?$209.08
Low?$206.86
Prev. Close?$208.50
Volume?2.5K
Avg. Volume?6.5M
VWAP?$208.21
Rel. Volume?0.00x
Bid / Ask
Bid?$207.25 × 100
Ask?$209.50 × 700
Spread?$2.25
Midpoint?$208.38
Valuation & Ratios
Market Cap?368.4B
Shares Out?1.8B
Float?1.8B
Float %?100.0%
P/E Ratio?102.18
P/B Ratio?-55.34
EPS?$2.04
Dividend?3.21%
Ex-Dividend?N/A
News
Profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Themes
Employees
57.0K
Market Cap
367.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2012-12-10
Address
1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064
Phone: (847) 932-7900
NORTH CHICAGO, IL 60064
Phone: (847) 932-7900
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?0.80Weak
Quick Ratio?0.68Weak
Cash Ratio?0.22Low
Debt/Equity?-10.95Low
ValuationFAIRLY VALUED
Score67/100
P/E?102.2PRICEY▾
P/B?-55.34CHEAP▾
P/S?5.86FAIR▾
P/FCF?17.1CHEAP▾
EV/EBITDA?15.1FAIR▾
EV/Sales?6.87HIGH▾
Returns & Efficiency
ROE?-54.2%WEAK▾
ROA?2.6%WEAK▾
Cash Flow & Enterprise
FCF?$21.5B
Enterprise Value?$431.8B
Fundamentals ratios updated end of day